穴位埋植药线治疗过敏性紫癜效果观察

目的：观察穴位埋植药线治疗过敏性紫癜的临床疗效。方法：将过敏性紫癜患儿200例随机分为观察组和对照组各100例。对照组采用传统治疗方法即对症治疗＋肾上腺糖皮质激素应用，观察组采用双侧足三穴位埋植药线的方法。即患儿取坐位或仰卧位，在常规消毒和局麻下，用无菌手术缝合针引线，一侧足三里穴埋植卡介菌多糖浸泡的肠线，另一侧埋植核酸注射液浸泡肠线。双侧穴位埋植药线的深度均要达肌层，然后将露出表皮的线头用手术剪剪除，在用无菌敷料包扎固定。7d治疗1次，2次为1个疗程，连续治疗3个疗程。上述两组患者均治疗40d后评定整体疗效及典型症状消失的时间。数据进行统计学处理（x2检验，t检验）。结果：两组患者整体疗效比较，提示观察组优于对照组（P〈0.01），具有非常显著性差异。其典型症状如皮肤紫癜、消化道症状、关节症状、肾损害症状比较，也具有非常显著性差异（P〈0.01），观察组所用的时间均较对照组短。结论：采用足三里穴位埋植药线治疗过敏性紫癜效果好。

Acupoint implantable drug-line treatment for allergic purpura

Objective：To observe the clinical efficacy of the the acupoint implants the drug line for allergic purpura. Methods：200 children were randomly divided into observation group and control group of 100 patients, control group took traditional treatment methods that symptomatic treatment ＋glucocorticoid. The observation group was treated with bilateral foot three acupuncture points implantable drug line. Children take sitting or supine position, routine disinfection and under local anesthesia, sterile surgical suture needle leads the side of the foot the the Zusanli implants card BCG polysaccharide soaked catgut, the other side of the implant nucleic acid injection soak catgut. The bilateral acupoint implantable drug line depth of myometrial, then the exposed epidermis thread cut off with surgical scissors, with a sterile dressing fixed. 7 days of treatment, 2 times for a course of treatment, continuous treatment of 3 courses. The two groups of patients were treated for 40 days after the assessment of the overall efficacy and typical symptoms disappear. Data for statistical analysis （x2 test, t test）. Results：The overall efficacy of the two groups of patients compared prompted the observation group than the control group （P〈0.01）, has a very significant difference. Typical symptoms such as skin purpura, gastrointestinal symptoms, joint symptoms, symptoms of kidney damage in comparison, has a very significant difference （P〈0.01）, the time of the observation group shorter than those of the control group. Conclusion：The implantable drug using Zusanli line treatment of allergic purpura.